Company Description
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).
The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients.
In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies.
Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies.
Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications.
The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron.
The company is based in New York, New York.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Sandesh Seth |
Contact Details
Address: 100 Park Avenue, 23rd Floor New York, New York 10017 United States | |
| Phone | 646 677 3870 |
| Website | actiniumpharma.com |
Stock Details
| Ticker Symbol | ATNM |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001388320 |
| CUSIP Number | 00507W107 |
| ISIN Number | US00507W2061 |
| Employer ID | 88-0378336 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Sandesh C. Seth M.B.A., M.S. | Chairman and Chief Executive Officer |
| Steven O'Loughlin BS | Chief Financial Officer and Corporate Secretary |
| Dr. Paul Diamond Esq., Ph.D. | Vice President of Patent and Legal Counsel |
| Dr. Avinash Desai M.D. | Chief Medical Officer |
| Jenny Hsieh | Chief Strategy Officer |
| Sunitha Lakshminarayanan | Senior Vice President, Head of CMC and Product Development |
| Caroline Yarbrough | Chief Commercial Officer |
| Lynn M. Bodarky M.B.A. | Chief Business Officer |
| J. C. Simeon | Executive Director of Quality Assurance |
| Dr. Madhuri Vusirikala M.D. | Vice President of Clinical Development BMT and Cellular Therapy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 27, 2024 | 8-K | Current Report |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 6, 2024 | ARS | Filing |
| Nov 5, 2024 | 8-K | Current Report |
| Nov 5, 2024 | DEF 14A | Other definitive proxy statements |
| Nov 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 4, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Aug 5, 2024 | 10-Q | Quarterly Report |